Axsome Therapeutics, Inc. (AXSM) FinancialsAXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. (AXSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SUNOSI milestone revenue, accounting for 100.2% of total sales, equivalent to $218.92M. Other significant revenue streams include Auvelitv and Sunosi. Understanding this composition is critical for investors evaluating how AXSM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Axsome Therapeutics, Inc. maintains a gross margin of 93.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.42%, while the net margin is -23.50%. These profitability ratios, combined with a Return on Equity (ROE) of -245.10%, provide a clear picture of how effectively AXSM converts its operational activities into shareholder value.

In the context of the broader market, AXSM competes directly with industry leaders such as KRYS and APGE. With a market capitalization of $11.19B, it holds a leading position in the sector. When comparing efficiency, AXSM's gross margin of 93.06% stands against KRYS's 94.60% and APGE's N/A. Such benchmarking helps identify whether Axsome Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Axsome Therapeutics has shown significant revenue growth, with Q2 2026 revenue at $218.4 million, a 46% increase year-over-year. The gross margin is strong at 93.06%, but the company continues to operate at a loss, with a net income loss of $51.3 million in Q2 2026.